Daily non-political popular news in brief.
From clinical cancer research: rethinking therapeutic cancer vaccine trials
07-03-2007 · EurekAlert!Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?
Read more »
Keywords: clinical, cancer, research, rethinking, therapeutic, vaccine, trials, trial
« Previous | Next »
Similar news on "From clinical cancer research: rethinking therapeutic cancer vaccine trials":
- Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
08-01-2007 · EurekAlert!
A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to research published in the Aug. 1 issue of the journal Clinical Cancer Research.
Similar news · Read more »
- Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
09-28-2007 · EurekAlert!
An oral presentation covering interim results from a U.K. Phase Ia/Ib combination Reolysin and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute conference on Oct. 2, 2007.
Similar news · Read more »
- Scientists follow familiar TRAIL to new cancer therapy
07-09-2007 · EurekAlert!
A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research, published in the July issue of the journal Cancer Cell, published by Cell Press, provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor death receptor ligand against a variety of human cancers.
Similar news · Read more »
- UCSF brain tumor vaccine trial shows promising results
04-16-2007 · EurekAlert!
A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.
Similar news · Read more »
- MIT radar technology fights breast cancer
11-28-2007 · Massachusetts Institute of Technology (MIT)
Treating breast cancer with a type of heat therapy derived from MIT radar research can significantly increase the effectiveness of chemotherapy, according to results from the fourth clinical trial of the technique reported online Nov. 25.
Similar news · Read more »
- NIAID DNA vaccine for H5N1 avian influenza enters human trial
01-03-2007 · EurekAlert!
The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the NIH Institutes, designed the vaccine. The vaccine does not contain any infectious material from the influenza virus.
Similar news · Read more »
- Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
11-08-2006 · EurekAlert!
Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague.
Similar news · Read more »
- Pancreatic cancer vaccine halts progression of disease in some patients
04-17-2007 · EurekAlert!
A dendritic cell-based therapeutic vaccine for pancreatic cancer developed by researchers at the University of Pittsburgh School of Medicine has successfully stalled the disease from progressing in a handful of patients three years post-vaccination. The results, part of a press briefing on cancer vaccines held at the annual meeting of the American Association of Cancer Research, provide promising evidence that the vaccine can trigger a patient's own immune system to rally against pancreatic cancer.
Similar news · Read more »
- Clinical Trials Directive still hampering academic medical research
09-27-2007 · EurekAlert!
The Clinical Trials Directive, which came into force in May 2004 in order to create a harmonized framework for clinical drug research across Europe, is still hampering such research, according to new findings presented at the European Cancer Conference.
Similar news · Read more »
- Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia
12-09-2007 · EurekAlert!
Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at the University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
Similar news · Read more »
